单倍体造血干细胞移植治疗重型地中海贫血:IV期开放标签单中心试验
该IV期开放标签单中心试验纳入134例输血依赖型地中海贫血患者,中位年龄8.7岁,均接受统一预处理方案及GVHD预防。主要终点2年总生存率为93.4%,2年无事件生存率和GRFS分别为92.6%和77.5%。供者特异性抗体及男受者/女供者配对与较差OS和EFS相关,肝肿大(≥5 cm)与较差OS相关。
要点
- 2年OS达93.4%,支持单倍体HSCT作为无全合供者TDT患者的治愈选择
- 供者特异性抗体和男受者/女供者配对与较差OS和EFS相关
- 肝肿大≥5 cm与较差OS相关
核心结论
- 单倍体HSCT可作为无全合供者输血依赖型地中海贫血患者的关键治愈选择。
研究设计与样本
- IV期开放标签单中心临床试验,纳入134例输血依赖型地中海贫血患者,中位年龄8.7岁(IQR 6.0-11.7,范围3-20)。
- 所有患者接受统一预处理方案(白消安、环磷酰胺、氟达拉滨和抗胸腺细胞球蛋白)及GVHD预防(甲氨蝶呤、吗替麦考酚酯和他克莫司)。
- 主要终点为2年总生存率,中位随访23.4个月(IQR 11.5-38.7,范围6.1-81.5)。
主要发现
- 2年OS、EFS和GRFS分别为93.4%、92.6%和77.5%。
- aGVHD、2-4级aGVHD和3-4级aGVHD的累积发生率分别为47.8%、30.9%和12.5%。
- 供者特异性抗体与较差OS(p=0.021)和EFS(p=0.040)相关。
- 男受者/女供者配对与较差OS(p=0.010)和EFS(p=0.020)相关。
- 肝肿大(≥5 cm)与较差OS相关(p=0.037)。
临床怎么用
- 对于无全合供者的输血依赖型地中海贫血患者,可考虑单倍体HSCT作为治愈性治疗。
- 移植前应评估供者特异性抗体及供受者性别配对,以识别高风险患者。
- 肝肿大≥5 cm的患者移植预后可能较差,需加强管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report the results of an open-label, single-centre phase 4 clinical trial evaluating haploidentical haematopoietic stem cell transplantation (Haplo-HSCT) in patients with transfusion-dependent thalassaemia (TDT). A total of 134 patients with TDT were enrolled; the median age was 8.7 years (interquartile range [IQR], 6.0-11.7 years; range, 3-20 years). All patients received a uniform conditioning regimen consisting of busulfan, cyclophosphamide, fludarabine and anti-thymocyte globulin (ATG). Graft-versus-host disease (GVHD) prophylaxis included methotrexate (MTX), mycophenolate mofetil (MMF) and tacrolimus. The primary end-point was 2-year overall survival (OS). Median follow-up is 23.4 months (IQR: 11.5-38.7; range: 6.1-81.5). The 2-year OS, event-free survival (EFS) and graft-versus-host disease-free, relapse-free survival (GRFS) rates were 93.4%, 92.6% and 77.5% respectively. The cumulative incidence rates of aGVHD, grade 2-4 aGVHD and grade 3-4 aGVHD were 47.8%, 30.9% and 12.5% respectively. Donor-specific antibodies (DSAs) and male-recipient/female-donor pairing were associated with inferior OS (p = 0.021; p = 0.010) and EFS (p = 0.040; p = 0.020). Hepatomegaly (≥5 cm) was associated with inferior OS (p = 0.037). Collectively, these findings support Haplo-HSCT as a key curative option for TDT patients in the absence of fully matched donors.
引用
- Lai X, Liu R, Xiao H, et al. Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial. Br J Haematol. 2026. PMID: 42680144. doi:10.1111/bjh.70819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。